Harrow Health Inc (HROW) shares surged 24.14% in pre-market trading on Tuesday, following the company's announcement of better-than-expected preliminary fourth-quarter results and a positive outlook for 2025. The eye-care pharmaceutical company's strong performance has caught investors' attention, driving significant interest in the stock.

According to the preliminary results released after Monday's closing bell, Harrow expects to report a profit of $5 million to $7 million on revenue of $65 million to $67 million for the fourth quarter. This forecast significantly outperforms Wall Street's expectations, as analysts surveyed by FactSet had anticipated a fourth-quarter loss of $300,000 on sales of $58.4 million. The company's ability to turn an expected loss into a substantial profit has clearly impressed investors.

Adding to the positive sentiment, Harrow's Chief Executive Mark Baum provided an initial 2025 outlook, projecting revenue of over $280 million for the year. This projection aligns closely with analysts' models, which predicted sales of $281.2 million. The strong Q4 results, combined with the optimistic future outlook, have contributed to the substantial pre-market rally. However, it's worth noting that the company delayed the release of its audited financial statements, as its new auditor required additional time to prepare the financial presentation. Despite this delay, CEO Baum reassured investors of the company's commitment to comprehensive, accurate, and transparent financial reporting.